lilli lower adj ep midpoint
reflect loxo lartruvo hit partial off-set
favor busi trend lower tax rate guidanc
revenue consensu adj ep
line
math reduct ep guidanc midpoint loxo hit
wors expect off-set favor busi trend lower
tax rate reduc lilli ir convey lartruvo loxo
calcul tax rate back favor busi trend
net figur
summari total compani perform revenu
con ep in-lin con
ep downsid vs model includ revenu
count i/ yoy growth nutshel rev gross profit oper
revenu beat revenu
basaglar jardianc
trulic tradjenta
olumi
alimta
revenu miss humalog humulin
forteo
verzenio cyramza
taltz
guidanc lower detail revenu guidanc prev
midpoint con
ep guidanc prev midpoint
con
 guidanc rais sg unchang
pleas refer variat tabl follow
major pharmaceut unit state america
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
per share equat approxim pre-tax
jardiance/glyxambi gm receiv gp bi
tradjenta/jenta gm receiv gp bi
basaglar estimate gm share gp bi
olumi bari high royalti
jardiance/glyxambi gm receiv gp bi
tradjenta/jenta gm receiv gp bi
basaglar estimate gm share gp bi cog
olumi bari high royalti
valuat methodolog risk
base case ep repres premium peer median due
risk achiev price target
upsid risk posit financi result project new product revenu
disappoint compel extern strateg action
downsid risk financi result fall short expect face us price
pressur trial disappoint occur compet drug surpris upsid
